Boston Research & Management Inc. Lowers Stock Holdings in VanEck Biotech ETF $BBH

Boston Research & Management Inc. lessened its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 4.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,812 shares of the company’s stock after selling 499 shares during the quarter. Boston Research & Management Inc. owned approximately 0.51% of VanEck Biotech ETF worth $1,657,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in BBH. Cetera Investment Advisers increased its stake in VanEck Biotech ETF by 15.8% in the first quarter. Cetera Investment Advisers now owns 3,094 shares of the company’s stock valued at $487,000 after purchasing an additional 423 shares during the last quarter. SVB Wealth LLC purchased a new stake in VanEck Biotech ETF in the 1st quarter valued at about $90,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of VanEck Biotech ETF by 8.3% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 22,361 shares of the company’s stock valued at $3,518,000 after acquiring an additional 1,705 shares during the last quarter. Strategic Financial Services Inc. purchased a new position in shares of VanEck Biotech ETF during the 1st quarter worth about $203,000. Finally, EWG Elevate Inc. acquired a new stake in shares of VanEck Biotech ETF in the second quarter worth approximately $363,000. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

VanEck Biotech ETF stock opened at $192.33 on Friday. VanEck Biotech ETF has a 1 year low of $135.34 and a 1 year high of $193.68. The firm has a 50 day moving average price of $176.36 and a 200 day moving average price of $163.83.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.